Large Granular Lymphocytic Leukemia Market
Number of pages: 100 | Report Format: PDF | Published date: 02 March, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 2,380.13 million |
|
Revenue forecast in 2031 |
US$ 7,630.76 million |
|
Growth Rate |
CAGR of 13.82% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Drug Class, Distribution Channel, and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global large granular lymphocytic leukemia market was valued at US$ 2,380.13 million in 2022 and is expected to register a revenue CAGR of 13.82% to reach US$ 7,630.76 million by 2031.
Market Fundamentals
Large granular lymphocytic (LGL) leukemia is a chronic mature lymphoproliferative disorder of the T/NK lineage. Majorly there are two kinds of large granular lymphocytic T-LGL leukemia and aggressive NK-cell leukemia. This classification system was approved by the World Health Organization (WHO) in 2001. T-LGL leukemia and chronic NK-cell lymphocytosis share clinical and biological characteristics, as well as treatment options.
The cause of LGL leukemia is yet unknown. A genetic alteration or mutation, often to the STAT3 and STAT5b genes, is linked to the disorder. The percentage of people with LGL leukemia who have a history of autoimmune diseases ranges from 10 to 40%. However, some research also suggests that rheumatoid arthritis is frequently linked to large granular leukemia. Both types of large granular lymphocytic leukemia develop slowly. People above 60 years of age are usually more prone to develop this disease. Large granular lymphocytic leukemia can be treated by medical professionals, but occasionally the disease persists and can develop into a chronic health problem.
The majority of individuals with chronic T-cell and NK-cell LGL leukemia present for diagnosis with similar symptoms such as a reduction in red blood cell synthesis (Anemia) affects around half of the patients, a low concentration of neutrophils, and a kind of white blood cell. Moreover, ongoing infections, fever, sweating at night, unintended loss of weight, and splenomegaly are some other serious symptoms.
[5754675]
Market Dynamics
The increasing prevalence of large granular lymphocytes is the prominent factor increasing the market revenue growth globally. According to the estimates of the National Organization for Rare Disorders, in 2022 there are 0.2 to 0.72 instances of large granular lymphocytes in the U.S. for every 1,000,000 people, however, this number may be low as there are individuals without symptoms or those with the disease in its early stages are undetected.
Increasing research and development for large lymphocytic leukemia is also a potential factor anticipated to increase the market revenue growth in the forecast period. For instance, current research predicted that several clinical reports have shown connections between the frequency of LGL leukemia and stem cells, bone marrow, and solid organ transplantation. Also, there is a chance that LGL leukemia will go undiagnosed among people with rheumatoid arthritis, which highlights the importance of further research.
The presence of pipeline drugs in the market is also attributed to increase the global large granular lymphocytic leukemia market. Moreover, the global large granular lymphocytic leukemia market revenue growth is also influenced by the support from several non-profit organizations that help underinsured individuals with large lymphocytic leukemia. For instance, leukemia & lymphoma society, The organization acts as a voice for all blood cancer patients seeking access to high-quality, fairly priced, coordinated treatment and contributes money for life-saving blood cancer research around the world. It also offers free information and support services.
However, the global large granular lymphocytic leukemia market will experience limited revenue growth in middle-income countries such as Middle East and Africa where healthcare standards are not advanced. This is mainly due to high prices of drugs, and therapies for treating large granular lymphocytic leukemia market.
Market Ecosystem
The global large granular lymphocytic leukemia market has been analyzed from three perspectives: Drug Class, Distribution Channel, and Region.
Large Granular Lymphocytic Leukemia Market by Drug Class
[854674]
Based on drug class, the global large granular lymphocytic leukemia market has been segmented into antineoplastics, immunosuppressants, alkylating agents, monoclonal antibodies, and other drug class.
Antineoplastics segment has dominated the global large granular lymphocytic leukemia market with largest revenue share in 2022. The antineoplastics drugs are used as first line of treatment for large lymphocytic leukemia. Antineoplastics drugs prevents cell proliferation and prevents cancer from spreading improving the survival rates of people with large lymphocytic leukemia. Moreover, the side effects of these drugs are generally mild than other drugs. The cost of antineoplastics drugs can also be comparatively lower, making them a more viable option for patients. Moreover, studies have shown that antineoplastics drugs have been able to reduce the size of tumors and have also been found to reduce the risk of relapse in large lymphocytic leukemia patients.
Monoclonal antibodies segment is anticipated to show highest revenue growth in forecast period. This is majorly attributed to recommendation of monoclonal antibodies as second-line treatment for large granular lymphocytic leukemia. Additionally, the revenue growth of monoclonal antibodies is also influenced by presence of many pipeline monoclonal antibody drugs. Moreover, these drugs are highly effective in targeting malignant cells and can be used in combination with traditional chemotherapy to reduce the risk of relapse. Additionally, they have fewer side effects than traditional therapies, which can be a major benefit for cancer patients. Additionally, monoclonal antibodies are undergoing many new advancements in treating large lymphocytic leukemia.
Large Granular Lymphocytic Leukemia Market by Distribution Channel
Based on distribution channel, the global large granular lymphocytic leukemia market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Hospital pharmacies segment has majority of the global large granular lymphocytic leukemia market revenue share. large granular. Hospital pharmacies offer a drug with guaranteed quality, affordable costs, and access to information and proper guidance about the drugs. Additionally, the segment is also supported by high footfall of patients in hospitals.
Large Granular Lymphocytic Leukemia Market by Region
Based on region, the global large granular lymphocytic leukemia market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America currently leads the global granular lymphocytic leukemia market owing to increased prevalence of granular lymphocytic leukemia. Large granular lymphocytic leukemia is most frequently reported in patients from North America, half of them also have autoimmune disorder such as rheumatoid arthritis. Moreover, presence of many market players involved in development of drugs for global granular lymphocytic leukemia is also supporting market revenue growth in North America. Increasing research and development for advancing diagnosis and treatment for granular lymphocytic leukemia is also increasing the global granular lymphocytic leukemia market revenue growth.
The European region for large granular lymphocytic leukemia market is characterized by increasing healthcare standards offering better diagnosis and treatment. Moreover, the global large granular lymphocytic leukemia market is also increasing as government support for large granular lymphocytic research and development initiatives have provided further growth of this market.
The global large granular lymphocytic leukemia market in Asia Pacific is likely to grow at high CAGR during the forecast period. This is owing to an increase in healthcare standards and the launch in new diagnosis and treatment options. Moreover, government initiatives in providing fundings for treatment of large granular lymphocytic leukemia is another factor increasing the large granular lymphocytic leukemia market in Asia Pacific.
Competitive Landscape
To increase their market position in the large granular lymphocytic leukemia market, the leading players are increasingly focusing on implementing tactics such as adopting recent technology, product developments, mergers and acquisitions, joint ventures, alliances, and partnerships. Companies are growing their operations and improving their presence through acquisitions. Focused research and development efforts (R&D) enabled the company to develop innovative products and a broad pipeline of potential new medicines, leading to revenue growth and helping it to secure brand image. Some of the prominent market players in the global large granular lymphocytic leukemia market include:
Strategic developments
High prevalence of the disease and advancements in treatment and diagnosis will increase the global large granular lymphocytic leukemia market.
Some of the prominent market players in the global large granular lymphocytic leukemia market include Bristol Myers Squibb and Company, GSK Plc, Sanofi SA, and Emcure Pharma so on.
The monoclonal antibodies segment is anticipated to grow at a rapid pace.
Asia Pacific is expected to mark the highest revenue growth during the forecast period.
The high cost of drugs and low standards of healthcare in middle-income countries are the most prominent restraints in the global large granular lymphocytic leukemia market.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst